AI Article Synopsis
Article Abstract
Background: Studies on cytochrome P450 (CYP) 2A6 suggest that genotype affects the rate of nicotine metabolism and, consequently, cigarette consumption. However, known alleles of CYP2A6 associated with fast or slow metabolism are relatively uncommon, and there remains considerable variation in metabolic activity among those with presumed wild-type CYP2A6 alleles, suggesting that other genetic or environmental factors also influence the rate of nicotine metabolism.
Methods: We investigated determinants of the rate of nicotine metabolism and effects on smoking behavior in a United Kingdom cohort who participated in a placebo-controlled trial of smoking cessation via nicotine replacement therapy. Those who continued to smoke cigarettes at the 8-year follow-up formed our study group (N = 545). The ratio of the nicotine metabolite trans-3'-hydroxycotinine to cotinine in plasma was used as an index of CYP2A6 activity and thus as a marker of the rate of nicotine metabolism.
Results: The nicotine metabolite ratio was associated with sex (P < .0001), CYP2A6 genotype (*1B, *2, *4, *9, and *12) (P < .0001), CYP2B6 haplotype (*4-dominant) (P = .02), plasma nicotine concentration (P < .0001), and age (P = .02) but was not associated with dependence score (P > .20). The ratio also predicted the number of cigarettes smoked at will per day, although the association was weak (F(1, 492) = 4.05, P = .04).
Conclusion: In this cohort the rate of nicotine metabolism is related to age, sex, CYP2A6 genotype, and CYP2B6 genotype and may affect the level of tobacco consumption.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.clpt.2006.06.011 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Low Psychological Resilience Predict the Risk for Alcohol Use Disorder in General Population: National Mental Health Survey of Korea 2021.
Clin Psychopharmacol Neurosci
February 2025
Department of Psychiatry, Korea University Guro Hospital, College of Medicine, Korea University, Seoul, Korea.
Objective: Prior research has emphasized psychological resilience as a potential protective factor against alcohol use disorder in diverse populations, with limited exploration of its relationship in the general population. This study investigated the association between the lifetime and one-year prevalence of alcohol use disorder and resilience.
Methods: Data obtained from the National Mental Health Survey of Korea 2021 (5,511 participants; 40.
Increasing a Quitline's Reach to Low-Income Tobacco Users Through 211 Agencies.
Nicotine Tob Res
January 2025
California Tobacco Prevention Program, California Department of Public Health, Sacramento, CA, USA.
Introduction: Low-income individuals bear a disproportionate share of the burden of tobacco use. This study tested the feasibility of increasing a quitline's reach to low-income tobacco users by collaborating with 211 information and referral agencies, which primarily serve people experiencing economic hardship.
Aims And Methods: Study participants (N = 114 888) were adult tobacco users referred to the California quitline by 211 agencies, referred by healthcare clinics, or self-referred from April 17, 2021 to December 31, 2023.
Smoking Cessation Interventions in the Lung Cancer Screening Setting: A Randomized Clinical Trial.
JAMA Intern Med
January 2025
Department of Behavioral Science, The University of Texas MD Anderson Cancer Center, Houston.
Importance: The optimal configuration of a smoking cessation intervention in a lung cancer screening (LCS) setting has not yet been established.
Objective: To evaluate the efficacy of 3 tobacco treatment strategies of increasing integration and intensity in the LCS setting.
Design, Setting, And Participants: In this randomized clinical trial, LCS-eligible current smokers were randomized into 3 treatments: quitline (QL), QL plus (QL+), or integrated care (IC).
Genome-wide association study of varenicline-aided smoking cessation.
Nicotine Tob Res
January 2025
Department of Population Health Sciences, University of Leicester, Leicester, UK.
Introduction: Varenicline is an α4β2 nicotinic acetylcholine receptor partial agonist with the highest therapeutic efficacy of any pharmacological smoking cessation aid and a 12-month cessation rate of 26%. Genetic variation may be associated with varenicline response, but to date no genome-wide association studies of varenicline response have been published.
Methods: In this study, we investigated the genetic contribution to varenicline effectiveness using two electronic health record-derived phenotypes.
Neuroanatomical Variability and Substance Use Initiation in Late Childhood and Early Adolescence.
JAMA Netw Open
December 2024
Department of Psychological and Brain Sciences, Washington University in St Louis, Missouri.
Importance: The extent to which neuroanatomical variability associated with early substance involvement, which is associated with subsequent risk for substance use disorder development, reflects preexisting risk and/or consequences of substance exposure remains poorly understood.
Objective: To examine neuroanatomical features associated with early substance use initiation and to what extent associations may reflect preexisting vulnerability.
Design, Setting, And Participants: Cohort study using data from baseline through 3-year follow-up assessments of the ongoing longitudinal Adolescent Brain Cognitive Development Study.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!